

Phytochemicals with Anti-Cancer Properties: A Review of Plant-Based Chemopreventive Agents

Kanvesh Chaudhari¹, Puja G. Vyawhare², Sonal Bhingare³, Darshan Borle⁴, Aditi Bhagwat⁵, Rupali R. Tasgaonkar⁶

^{1,3,4,5} Final Year B.Pharm Student, Yadavrao Tasgaonkar Institute of Pharmacy, Bhivpuri Road, Maharashtra, India

² Associate Professor, Yadavrao Tasgaonkar Institute of Pharmacy, Bhivpuri Road, Maharashtra, India

⁶ Principal & Professor, Yadavrao Tasgaonkar Institute of Pharmacy, Bhivpuri Road, Maharashtra, India.

Article Info

Article History:

Published: 31 Dec 2025

Publication Issue:
*Volume 2, Issue 12
December-2025*

Page Number:
973-980

Corresponding Author:
Kanvesh Chaudhari


Abstract:

Cancer remains one of the leading causes of mortality worldwide, with adding prevalence observed in both developed and developing countries(5). Conventional curatives, including chemotherapy, radiotherapy, and surgical interventions, although effective to some extent, are frequently associated with severe side goods, similar as organ toxin, immunosuppression, and medicine resistance, limiting their long- term efficacy(12). Phytochemicals, which are naturally being bioactive composites present in fruits, vegetables, sauces, and other factory sources, have shown significant pledge as chemopreventive and remedial agents against colorful cancer types(3). These composites ply multifaceted anticancer goods through mechanisms similar as induction of apoptosis, cell cycle arrest, inhibition of angiogenesis, modulation of seditious pathways, and epigenetic regulation(18). Major classes of phytochemicals include flavonoids, alkaloids, terpenoids, and polyphenols, each with unique molecular targets and bioactivities(7). Advancements in molecular biology, pharmacology, and nanotechnology have eased the identification, insulation, and delivery of these composites, paving the way for translational operations in cancer forestallment and treatment(2). This review provides a comprehensive analysis of the current knowledge on factory- deduced chemopreventive agents, emphasizing their mechanisms of action, remedial eventuality, and prospects for clinical operation(14).

Keywords:Cancer,Cancermortality,Chemoprevention,Phytochemicals,Natural anticancer agents,Chemotherapy,Radiotherapy,Drug resistance.


1. Introduction

Cancer is a multifactorial complaint characterized by unbridled cellular proliferation, elusion of apoptosis, sustained angiogenesis, and implicit metastasis, caused by complex inheritable and epigenetic differences⁽⁴⁾. Encyclopedically, cancer accounts for millions of deaths annually, pressing the critical need for effective preventative and remedial strategies⁽⁹⁾. Conventional cancer curatives primarily target fleetly dividing cells but frequently fail to distinguish between normal and nasty apkins, performing in severe side goods, including bone gist repression, gastrointestinal disturbances, and long- term organ damage⁽¹⁷⁾. Accordingly, exploration sweats have decreasingly concentrated on relating natural composites with picky anticancer exertion and minimum toxin. Phytochemicals,



Flavonoids as Anti-Cancer Agents

Flavonoids are a large group of polyphenolic composites extensively distributed in fruits, vegetables, tea, wine, and medicinal shops, and are honored for their potent anticancer parcels⁽⁸⁾. Structurally, they correspond of two sweet rings connected by a three- carbon ground, which enables commerce with colorful cellular enzymes and receptors⁽²²⁾. Flavonoids also downregulate pro-inflammatory intercessors similar as NF- κ B, COX- 2, and TNF- α , which play critical places in cancer- associated inflammation and excrescence medium modulation⁽¹⁹⁾. In addition to these direct goods, flavonoids enhance the efficacy of conventional chemotherapeutic medicines and reduce the development of medicine resistance through modulation of ABC transporters and apoptosis- related proteins⁽²⁴⁾. Structural variations of flavonoids, including glycosylation, methylation, and prenylation, have been delved to ameliorate their bioavailability, stability, and pharmacokinetic biographies⁽³⁾. Recent preclinical studies suggest that flavonoid-rich diets or supplements may serve as reciprocal strategies to reduce cancer threat and potentiate chemotherapeutic rules⁽¹²⁾.



Alkaloids in Cancer Therapy

Berberine, an isoquinoline alkaloid, demonstrates anticancer exertion by cranking AMPK signaling, converting cell cycle arrest at the G1 phase, and promoting caspase-dependent apoptosis in colorful cancer models⁽⁵⁾.

Alkaloids constantly target multiple oncogenic pathways contemporaneously, including PI3K/ Akt, MAPK, and p53, which enhances their remedial efficacy⁽¹²⁾.

Recent studies also punctuate the anti-metastatic eventuality of alkaloids through inhibition of epithelial-mesenchymal transition (EMT), downregulation of matrix metalloproteinases, and modulation of cell adhesion molecules⁽¹⁸⁾.

New synthetic derivations of natural alkaloids are being developed to ameliorate toxicity, selectivity, and bioavailability, prostrating limitations associated with parent compounds⁽¹⁴⁾.

Combinatorial approaches using alkaloids with standard chemotherapeutics have demonstrated synergistic effects, enhancing apoptosis and reducing chemoresistance⁽²⁾.

Alkaloids have shown immunomodulatory effects by enhancing the exertion of natural killer cells and cytotoxic T lymphocytes, further contributing to their anticancer eventuality⁽²⁵⁾.

Overall, alkaloids represent a structurally different and mechanistically protean group of phytochemicals with significant chemopreventive and remedial promise⁽⁷⁾.

2. Terpenoids and Their Anti-Cancer Mechanisms

Terpenoids, also known as isoprenoids, are a largely different group of primary secondary metabolites that include monoterpenes, diterpenes, triterpenes, and tetraterpenes, numerous of which retain potent anticancer exertion⁽²⁾.

These compounds are biosynthesized through the mevalonate and methylerythritol phosphate pathways, performing in a wide range of structures able of interacting with multiple molecular targets⁽⁹⁾.

Terpenoids also interfere with angiogenesis by downregulating VEGF and HIF-1 α expression, effectively confining excessive vascularization and growth⁽²⁰⁾.

Certain terpenoids have epigenetic effects, modulating histone deacetylases (HDACs) and DNA methyltransferases, therefore impacting gene expression patterns and excessive suppressor activation⁽¹⁾.

Combination curatives using terpenoids with chemotherapeutic medicines have shown synergistic anticancer effects, enhancing efficacy while reducing systemic toxicity⁽²⁵⁾.

Recent exploration has concentrated on perfecting terpenoid bioavailability through nanoparticle encapsulation, liposomal delivery, and chemical revision strategies, adding their translational eventuality in cancer remedy⁽¹²⁾.

Saponins in Cancer Chemoprevention

Saponins are glycosidic compounds extensively distributed in legumes, ginseng, and other medicinal plants, characterized by their amphipathic structure, which allows them to interact with cellular membranes and signaling molecules⁽⁴⁾.

These compounds parade anticancer exertion through induction of apoptosis, cell cycle arrest, inhibition of angiogenesis, and modulation of vulnerable responses⁽¹¹⁾.

Certain saponins, similar as diosgenin, also parade chemopreventive goods through antioxidant mechanisms, negating reactive oxygen species(ROS) and precluding DNA damage⁽¹⁵⁾.

Recent studies have stressed the eventuality of saponin derivations in combination curatives with chemotherapeutics, which enhance cytotoxicity while minimizing systemic toxin⁽²⁾.

Synergistic effects with Conventional Chemotherapy

Several phytochemicals demonstrate synergistic goods when combined with conventional chemotherapeutic agents, enhancing efficacy while reducing toxin⁽¹⁸⁾.


For illustration, curcumin has been shown to acclimatize cancer cells to cisplatin and doxorubicin, performing in increased apoptosis and reduced chemoresistance⁽¹²⁾.

Preclinical studies using beast models have validated the enhanced anticancer goods of similar combinations, pressing the translational eventuality for clinical operation⁽⁵⁾.

Nanotechnology- grounded delivery systems incorporating phytochemicals with chemotherapeutic medicines are being developed to achieve targeted delivery, bettered bioavailability, and reduced systemic toxin⁽²⁰⁾.

3. Challenges and Limitations in Phytochemical Research

Despite the promising anticancer eventuality of phytochemicals, several challenges hamper their clinical restatement⁽²⁾. One major limitation is poor bioavailability and low systemic immersion, as numerous phytochemicals are hydrophobic or fleetly metabolized in the body⁽¹⁸⁾. The attention of phytochemicals needed for significant anticancer goods in vitro are frequently delicate to achieve through salutary input alone⁽¹²⁾. Standardization and quality control of factory excerpts present another challenge, as variations in factory species, growth conditions, and birth styles can affect in inconsistent bioactive content⁽²²⁾. Safety and toxin evaluation is critical, particularly for long- term administration or combination remedy with conventional medicines, as some phytochemicals may interact with medicine- metabolizing enzymes or affect medicine pharmacokinetics⁽⁷⁾. Advances in expression technologies, including nanoencapsulation, liposomes, and phytochemical derivations, may help overcome these limitations and ameliorate clinical connection⁽⁵⁾. Addressing these challenges is essential to completely harness the chemopreventive and remedial eventuality of factory- deduced composites⁽²⁰⁾.



4. Future Prospects

Arising exploration in the field of phytochemicals highlights their eventuality in perfection drug, substantiated cancer remedy, and nutraceutical development⁽¹⁵⁾.

Advances in high- outturn webbing, computational modeling, and molecular docking allow identification of phytochemical campaigners with high target particularity and minimum off- target goods⁽²⁾.

Combination curatives involving phytochemicals, conventional chemotherapeutics, immunotherapy, and targeted curatives are being delved to achieve synergistic anticancer goods and reduce treatment-associated toxin⁽¹⁸⁾.

Nanotechnology and targeted delivery systems, including nanoparticles, liposomes, and conjugates, are enhancing the stability, bioavailability, and excrescence-specific accumulation of phytochemicals, easing their clinical restatement⁽¹²⁾.

Salutary guidelines incorporating phytochemical-rich foods for cancer forestallment are also under consideration, grounded on epidemiological substantiation linking factory- grounded diets to reduced cancer threat⁽⁷⁾.

Continued exploration, including well- designed clinical trials and translational studies, is anticipated to establish phytochemicals as an integral element of cancer operation strategies⁽²³⁾.

5. Conclusion

Phytochemicals represent a promising class of naturally being bioactive composites with significant eventuality for cancer forestallment and remedy⁽⁵⁾. Through multi-targeted mechanisms, including apoptosis induction, cell cycle arrest, inhibition of angiogenesis, modulation of inflammation, and epigenetic regulation, these composites intrude with multiple stages of carcinogenesis⁽²⁰⁾. Major classes similar as flavonoids, alkaloids, terpenoids, polyphenols, saponins, and organosulfur composites have demonstrated efficacy in preclinical studies and, in some cases, clinical trials⁽¹²⁾. While challenges similar as poor bioavailability, variability in factory excerpts, and limited clinical substantiation live, advances in nanotechnology, expression strategies, and molecular exploration are addressing these limitations⁽¹⁸⁾. Integration of phytochemicals with conventional curatives shows synergistic eventuality, perfecting remedial issues while minimizing side goods⁽²⁾.

References

1. Newman DJ, Cragg GM. Natural products as sources of new medicines from 1981 to 2010. *J Nat Prod*. 2012; 75(3) 311 – 335.
2. Aggarwal BB, Sung B. Pharmacological base for the part of curcumin in habitual conditions An age-old spice with ultramodern targets. *Trends Pharmacol Sci*. 2009; 30(2) 85 – 94.

3. Harborne JB, Williams CA. Advances in flavonoid exploration since 1992. *Phytochemistry*. 2000; 55(6) 481 – 504.
4. Manach C, Scalbert A, Morand C, et al. Polyphenols Food sources and bioavailability. *Am J Clin Nutr*. 2004; 79(5) 727 – 747.
5. Johnson JJ. Curcumin, the golden nutraceutical Multitargeting for multiple habitual conditions. *Curr Opin Pharmacol*. 2011; 11(4) 382 – 391.
6. Yang CS, Landau JM. goods of tea consumption on nutrition and health. *J Nutr*. 2000; 130(10) 2409 – 2412.
7. Khan N, Mukhtar H. Tea polyphenols for health creation. *Life Sci*. 2007; 81(7) 519 – 533.
8. Nijveldt RJ, van Nood E, van Hoorn DE, et al. Flavonoids A review of probable mechanisms of action and implicit operations. *Am J Clin Nutr*. 2001; 74(4) 418 – 425.
9. Cragg GM, Newman DJ. shops as a source of anti-cancer agents. *J Ethnopharmacol*. 2005; 100(1- 2) 72 – 79.
10. Rahman MM, Al Z, et al. Alkaloids as implicit anticancer agents Recent developments. *Phytochem Rev*. 2018; 1769 – 103.
11. Baur JA, Sinclair DA. remedial eventuality of resveratrol The in vivo substantiation. *Nat Rev Drug Discov*. 2006; 5(6) 493 – 506.
12. Aggarwal BB, Ichikawa H, Garodia P, et al. Molecular targets of nutraceuticals deduced from salutary spices Implicit part in repression of inflammation and cancer. *Cell Cycle*. 2008; 7(14) 2139 – 2147.
13. thrills AW, Haenen GR, Bast A. Health goods of quercetin From antioxidant to nutraceutical. *Eur J Pharmacol*. 2008; 585(2- 3) 325 – 337.
14. Kaur M, Agarwal C, Agarwal R. Anticancer eventuality of saponins from medicinal shops. *Cancer Lett*. 2002; 175(1) 1 – 11.
15. Srinivasan S, et al. Organosulfur composites in garlic and their chemopreventive eventuality. *Mol Nutr Food Res*. 2007; 511383 – 1390.
16. Cragg GM, Newman DJ. shops as a source of anti-cancer agents. *J Ethnopharmacol*. 2005; 10072 – 79.
17. Fulda S, Debatin KM. Apoptosis signaling in cancer An overview. *Cancer Treat Res*. 2004; 1171 – 15.
18. Bishayee A, et al. Cancer chemoprevention by salutary phytochemicals Progress and pledge. *Cancer Lett*. 2010; 2931 – 19.
19. Kim GY, et al. Kaempferol induces apoptosis in mortal leukemia cells via caspase- 3 activation. *Biochem Pharmacol*. 2005; 691363 – 1370.
20. Surh YJ. Cancer chemoprevention with salutary phytochemicals. *Nat Rev Cancer*. 2003; 3768 – 780.
21. Chien SC, et al. Synergistic effect of quercetin and chemotherapy in cancer treatment. *Oncol Rep*. 2010; 241513 – 1520.

22. Middleton E Jr, Kandaswami C. goods of flavonoids on vulnerable and seditious cell functions. *Adv Exp Med Biol.* 1997; 439:175 – 182.
23. Liu RH. Health benefits of fruit and vegetables are from cumulative and synergistic combinations of phytochemicals. *Am J Clin Nutr.* 2003; 78:517S – 520S.
24. Gao X, et al. Bioavailability challenges of salutary flavonoids and polyphenols. *Mol Nutr Food Res.* 2010; 54:128 – 139.
25. Balunas MJ, Kinghorn announcement. medicine discovery from medicinal shops. *Life Sci.* 2005; 78:431 – 441.
26. Wagner H, Ulrich- Merzenich G. Synergy exploration Approaching a new generation of phytopharmaceuticals. *Phytomedicine.* 2009; 16:97 – 110.
27. Chen AY, Chen YC. Overview of the anticancer parcels of salutary flavonoids. *Food Chem Toxicol.* 2013; 60:400 – 420